Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04523350 · ClinicalTrials.gov registry record · NA
Instylla HES Hypervascular Tumor Pivotal Study
A NA study, sponsored by Instylla.
- Completed
- Registry status
- NA
- Development phase
- 150
- Enrollment target
NCT04523350 is a NA study that has completed, run by Instylla. The registered enrollment target is 150 participants.
The verdict
NCT04523350, a NA study, has completed, sponsored by Instylla.
- COMPLETED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
Study Summary
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of device and procedure-related serious adverse events.
Interventions
- DEVICE Instylla HES
- OTHER TAE or cTACE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2024-11-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04523350
The ClinicalTrials.gov registry entry for NCT04523350 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Instylla, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Instylla HES is the first listed.
NCT04523350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04523350 about?
NCT04523350 is a clinical study titled "Instylla HES Hypervascular Tumor Pivotal Study". To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of ...
What is the current status of trial NCT04523350?
This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2021-03-05. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT04523350?
The interventions under investigation include: Instylla HES (DEVICE), TAE or cTACE (OTHER).
Who is sponsoring clinical trial NCT04523350?
This trial is sponsored by Instylla, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.